Heart failure drives hundreds of billions in annual global healthcare costs
The cost reflects a lack of precision targeted therapies that intervene before irreversible damage.
Digital twins of the living heart for real-time personalized heart failure therapy
CorSilico builds personalized heart digital twins from a standard blood draw. Our foundation model maps circulating cell-free RNA and DNA back to the source cells driving injury.
THE LIVING HEART, DECODED
cfRNA / cfDNA
SPATIAL INTELLIGENCE
SPATIAL INTELLIGENCE
PERSONALIZED.
RESOLVED IN REAL TIME.
RESOLVED IN REAL TIME.
+From circulating signals to cellular insight+
Scroll to explore Cardiology × Spatial genomics × AI
Recognized science. Exceptional pedigree.
Katz AwardAmerican Heart AssociationInnovative Project AwardAmerican Heart Association
Top 15 ventureCure MEHA II
Cardiology suffers from a massive diagnostic blind spot
Every patient has a unique disease signature
Diverse comorbidities create different populations of invasive cells that cause damage in each patient.
Living human hearts cannot be safely biopsied
Ultrasound and MRI detect historical damage after irreversible scarring has occurred. The cellular drivers remain hidden.
Untargeted therapeutics fail to cure complex heart failure
Net fishing all cells does not work
Recent high-profile clinical trial failures show that broad targeting of disease-causing and protective cells leads to clinical failure.
Precision requires the right cells, the right patient, and the right time
Without precisely targeting the damage-causing cell subsets, multi-million-dollar assets cannot match the right patient to the right drug at the correct time.
Our award-winning science: Specific cell subpopulations dictate heart injury
Our preclinical work discovered the cell subpopulations damaging the heart and mapped their spatial microenvironments. This spatial arrangement dictates disease trajectory and therapy response.
Katz AwardAmerican Heart Association
Innovative Project AwardAmerican Heart Association
Featured onAl Jazeera
Published in
Published inOur solution: Personalized heart digital twins from liquid biopsy
1
Preclinical ground truth
A foundation model trained on paired blood and heart tissue to map circulating cell-free RNA & DNA back to their source cells in the injured heart.
Foundation Model
The trained foundation model is used to create patient digital twins.
2
Digital twins
The model projects human liquid biopsy into a spatial latent space, generating personalized digital twins of the living heart.
Foundation Model
Identify real-time hidden pathology, before damage happens.
The virtual human heart
data engine.
The world’s first and largest data engine of human heart failure cell niches, longitudinally resolved to disease progression. A by-product of creating thousands of human heart failure digital twins.
Virtual human heart data engine
Proprietary IP
Discover heart failure therapeutic targets against specific cell subpopulations, directed to specific patient groups.
06 / Commercialization
Phased commercialization eradicates
clinical risk while capturing venture upside.
Commercialization begins with retrospective patient stratification for stalled heart-failure trials, followed by clinical theranostics licensing and therapeutic IP out-licensing.
$75M–$150M
Identify responders in stalled heart-failure trials
Near-term serviceable revenue from retrospectively stratifying just 5–10 stalled heart-failure trials. Identify the patients most likely to respond to targeted assets.
$213M–$1.06B+
License a clinical theranostics platform
Annual recurring revenue opportunity at a $15,000 diagnostic price, reaching 0.1%–0.5% of 13.2M+ eligible US patients. Preventing a 30-day readmission exceeding $27K per event underpins the value proposition.
$4B+
Out-license therapeutic targets to biopharma
Big Pharma partnerships shift clinical-trial execution to the partner. Precedent precision-therapy deals: $160M–$185M upfront, up to $4B+ in staggered pre-commercial milestones, and 12%–17% tiered royalties.
Company opportunity estimates and development strategy; figures are projections, not realized revenue. Precedent deal terms do not predict future agreements.
07 / Why now
Our in-house spatial-omics platform
shatters the data-generation bottleneck.
A multi-hundred-sample foundation AI model became economically possible for the first time.
Commercial platforms can cost up to $5,000 per tissue cross section. Our in-house spatial transcriptomics platform is designed to deliver high-definition tissue profiles at 15% of commercial cost—unlocking the scale a foundation model needs.
15%of commercial cost
In-house platform target
In-house platform target
Commercial platformsIn-house spatial omics
Technical moat, data flywheel,
and trade secrets.
Proprietary spatial transcriptomics and foundation model
Proprietary in-house spatial transcriptomics, the heart-failure foundation model, and a deconvolution pipeline designed to capture unstable, low-abundance circulating fragments.
Each digital twin improves the model
Every new digital twin improves the model. More paired data enables better mapping, attracting more partners and patients—and generating more data.
Proprietary training data and deconvolution pipelines
Proprietary architectures, training data, and deconvolution pipelines. Years of wet-lab R&D and tissue-handling expertise encode knowledge that cannot be copied from a dataset.
More data→Better mapping→More partners & patients→More data ↻
09 / The market
A multi-billion-dollar precision
heart-failure theranostics market.
TAM / DIAGNOSED US MARKET
$27.9B
Diagnosed US heart-failure patients
Company-estimated accessible market, based on conservative 30% access to 6.7M diagnosed US heart-failure patients and a $15,000 platform baseline cost.
SAM / PROSPECTIVE PRE-HF MARKET
6.5M–8.5M
Highest-risk Stage B patients
The top 10% highest-risk individuals within the Stage B pre-heart-failure population, targeted for prophylactic screening.
SOM / NEAR-TERM EXPONENTIAL CAPTURE
3 phases
Revenue across three commercialization phases
$75M–$150M in companion diagnostics. $213M–$1.06B+ in clinical theranostics ARR. Therapeutic IP with precedent upfront payments of $160M–$185M and up to $4B+ in milestones.
Company market estimates reproduced from the source materials. Figures are approximate and reflect separate addressable populations and commercialization assumptions.
10 / Roadmap & financing
Raising $1.3M to validate the foundation model and establish biopharma partnerships
Scientific and operational milestones achieved
- Award-winning science.
- Selected as a Top 15 venture by Deerfield-Cure MEHA II.
- Delaware C-Corp with clean, independent IP.
- Pre-clinical ground truth established.
- In-house scalable spatial transcriptomics platform.
- Proprietary pipelines based on years of R&D.
50%
Porcine heart-failure cohort 1 and spatial-to-liquid deconvolution.
30%
Key hires, BSL-2 lab, compute, and spatial-omics infrastructure.
20%
Early-access biopharma business development, provisional patent filings, and core operations.
Establish the porcine cohort and spatial platform
Establish the BSL-2 lab, validate the spatial platform, and launch porcine cohort 1.
Map circulating fragments to source cells
Pair tissue maps with circulating signals; complete the first ground-truth cohort.
Secure biopharma data agreements and trial-rescue pilots
Biopharma data agreements, trial-rescue pilots, and human digital-twin translation.
14-MONTH TARGET
Cash-flow positive.
Revenue from early-access biopharma partnerships is intended to fund further model development and cohort expansion.
Planned milestones and cash-flow timing are forward-looking targets.